181 related articles for article (PubMed ID: 31941753)
1. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
Manabe T; Yasuda H; Terai H; Kagiwada H; Hamamoto J; Ebisudani T; Kobayashi K; Masuzawa K; Ikemura S; Kawada I; Hayashi Y; Fukui K; Horimoto K; Fukunaga K; Soejima K
Mol Cancer Res; 2020 Apr; 18(4):549-559. PubMed ID: 31941753
[No Abstract] [Full Text] [Related]
2. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
3. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
4. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).
Tang YF; Liu ZH; Zhang LY; Shi SH; Xu S; Ma JA; Hu CH; Zou FW
Mol Cancer; 2024 May; 23(1):91. PubMed ID: 38715012
[TBL] [Abstract][Full Text] [Related]
5. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
6. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
7. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y
Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248
[No Abstract] [Full Text] [Related]
8. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
Cao L; Qin Z; Yu T; Bai X; Jiang S; Wang D; Ning F; Huang M; Jin J
Biochem Pharmacol; 2024 Jun; 224():116207. PubMed ID: 38621425
[TBL] [Abstract][Full Text] [Related]
9. ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.
Hou H; Sun D; Zhang C; Liu D; Zhang X
Thorac Cancer; 2021 Mar; 12(6):962-969. PubMed ID: 33506568
[TBL] [Abstract][Full Text] [Related]
10. Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling.
Lai L; Shen Q; Wang Y; Chen L; Lai J; Wu Z; Jiang H
Toxicol Appl Pharmacol; 2021 May; 419():115518. PubMed ID: 33812963
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
13. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R; Yamada T; Kita K; Taniguchi H; Arai S; Fukuda K; Terashima M; Ishimura A; Nishiyama A; Tanimoto A; Takeuchi S; Ohtsubo K; Yamashita K; Yamano T; Yoshimura A; Takayama K; Kaira K; Taniguchi Y; Atagi S; Uehara H; Hanayama R; Matsumoto I; Han X; Matsumoto K; Wang W; Suzuki T; Yano S
Nat Commun; 2020 Sep; 11(1):4607. PubMed ID: 32929081
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
15. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
16. Targeting
Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
[No Abstract] [Full Text] [Related]
17. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
18. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
[TBL] [Abstract][Full Text] [Related]
19. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
Jiang Y; Zhuo X; Wu Y; Fu X; Mao C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981
[TBL] [Abstract][Full Text] [Related]
20. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
Li L; Wang Y; Jiao L; Lin C; Lu C; Zhang K; Hu C; Ye J; Zhang D; Wu H; Feng M; He Y
Cancer Lett; 2019 Jun; 452():191-202. PubMed ID: 30910592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]